AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
BridgeBio Pharma’s acoramidis shows improved survival data, boosting approval chances. Read why BBIO stock could see gains if ...
Hosted on MSN1d
AstraZeneca plans major $3.5bn expansion drive in the USUK-based biopharmaceutical company AstraZeneca has announced a $3.5bn investment to expand its research and manufacturing ...
Bernstein analyst Justin Smith maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p18,000.00. Justin Smith has given his Buy rating due to a combination of ...
AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the end of 2026. This includes $2 billion ...
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on AstraZeneca (AZN – Research Report), with ...
All 11 sectors are in the green for the year. The optimism comes as the economy is likely to continue to grow because the ...
AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 17,821.63 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key ...
The Company History page lists out the major events in chronological order for AstraZeneca Pharma India Ltd. Company History - AstraZeneca Pharma India Ltd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback